Drug Profile
DMI 9523
Alternative Names: Ampion; DA-DKP; DM 9523; DMI-9523; LMWF 5ALatest Information Update: 24 Apr 2023
Price :
$50
*
At a glance
- Originator Ampio Pharmaceuticals
- Developer Ampio Pharmaceuticals; Vanderbilt University
- Class Antirheumatics; Dipeptides; Eye disorder therapies; Ketones; Nonsteroidal anti-inflammatories; Piperazines; Small molecules
- Mechanism of Action Cytokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; COVID 2019 infections; Crohn's disease; Eye disorders; Inflammation; Neurological disorders; Osteoarthritis; Post acute COVID 19 syndrome; Protein-losing enteropathy; Rhinitis; SARS-CoV-2 acute respiratory disease